Global Ptsd Therapeutics Market to Grow at a Cagr of 1.09 Percent over the Period 2014-2019

About PTSD

PTSD is a psychological condition that develops after a person is exposed to any traumatic event, and it drains a person emotionally. According to the DSM-IV codes found in the Diagnostic and Statistical Manual of Mental Disorders, published by the American Psychiatric Association (APA), PTSD is classified under anxiety disorders. PTSD can occur in individuals of any age, irrespective of the gender; its symptoms can develop immediately after a traumatic event or during the course of time. Its symptoms normally include re-experience of the traumatic event, avoidance of the incidents, and abnormal mood swings. Treatments for PTSD include psychological counselling, which help in identifying the cause of the condition and providing counselling to come out of the situation. Medications present in the market help in reducing the symptoms during the course of the treatment.

To Browse a Full Report with TOC: http://www.researchmoz.us/global-post-traumatic-stress-disorder-therapeutics-market-2015-2019-report.html

Technavio's analysts forecast the global PTSD therapeutics market to grow at a CAGR of 1.09% over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the global PTSD therapeutics market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various generic, off-label, and branded therapies used for the treatment of PTSD. This report includes the segmentation of the market based on geography.

Key Regions

Americas

APAC

EMEA

Key Vendors

GlaxoSmithKline

Pfizer

Otsuka Pharmaceutical

Other Prominent Vendors

Azevan Pharmaceuticals

Baylor Research Institute

Eli Lilly

Forest Laboratories

H. Lundbeck

Humanetics Pharmaceuticals

Marinus Pharmaceuticals

Nanotherapeutics

Neurocrine Biosciences

Novartis Pharmaceuticals

Synchroneuron

Tonix Pharmaceuticals

To Download Sample...